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The PARTNER (Placement of Aortic Transcath-
ter Valves) trial, recently published (1) and pre-
ented at the 2010 Transcatheter Cardiovascular
herapeutics conference, investigated the safety
nd efficacy of transcatheter aortic-valve implanta-
ion (TAVI) in patients deemed unsuitable for
urgical aortic valve replacement.
Severe calcific aortic stenosis (AS) is an increas-
ngly prevalent disease in elderly persons, with a
igh and rapid rate of mortality in untreated
atients, approaching 50% mortality over the first 2
ears (2). Aortic valve replacement is the current
old standard of treatment and has been proven to
rolong and improve quality of life in good oper-
tive candidates; however, in patients with multiple
r severe comorbidities and high operative risk,
urgery is often prohibitive (3,4). Transcatheter
ortic-valve implantation is a newer and less inva-
ive alternative approach that has demonstrated
avorable results and low mortality in these high-
urgical-risk patients in the PARTNER trial.
rial Summary
he PARTNER trial was a prospective, multi-
enter, randomized clinical trial designed to com-
are the outcomes of patients with symptomatic
evere AS (defined as an aortic valve area of 0.8
m2, a mean transvalvular gradient of at least 40 mm
g, or a peak aortic velocity of at least 4 m/s) by
reatment with either TAVI or standard medical
herapy. Patients selected were considered unsuitable
andidates for aortic valve replacement due to an
rom the *Division of Interventional Cardiology and Endovascular
edicine, Deborah Heart and Lung Center, Browns Mills, New Jersey;
Division of Interventional Cardiology, Mount Sinai Medical Center,
ew York, New York; and the ‡Interventional Cardiology, Beth Israel
eaconess Medical Center, Boston, Massachusetts. Dr. George is a
onsultant for Boston Scientific and ev3 Endovascular. Dr. Popma has
eceived research grants from Medtronic, Cordis, Boston Scientific,
bbott Vascular, and is a consultant for Cordis, Medtronic, St. Jude, andr
bbott. All other authors have reported that they have no relationships
o disclose.xceedingly high surgical risk, as determined by the
ociety of Thoracic Surgeons risk score.
A total of 358 patients were enrolled across 21
ites and followed for at least 1 year. The Edwards
APIEN heart-valve system (Edwards Life-
ciences, Inc., Irvine, California) was the biopros-
hetic aortic valve used for TAVI, consisting of a
rileaflet bovine pericardial valve and a balloon-
xpandable stainless steel support frame. Standard
edical therapy included balloon aortic valvulo-
lasty, which was performed in almost 65% of the
atients in the control arm within the first 30 days
fter randomization. The primary end point was the
ate of death from any cause at 30 days and 1 year,
nd secondary end points included the rate of death
rom cardiovascular causes, New York Heart Associ-
tion functional class status, rates of myocardial in-
arction, stroke, bleeding, and vascular complications.
The reported rate of death from any cause at 30
ays was nonsignificantly higher in the TAVI-treated
roup in comparison with the standard medical
herapy group (5.0% vs. 2.8%, respectively, p 0.41).
owever, at 1-year follow-up, the rate of death from
ny cause was significantly lower in the TAVI group
ompared with the medical treatment group (30.7%
s. 50.7%, p  0.001). In addition, the rate of death
rom cardiovascular causes was also lower in the
AVI arm versus the medical therapy arm (20.5% vs.
4.6%, respectively, p  0.001). Major strokes, al-
hough nonsignificant, were more common in pa-
ients who underwent TAVI at 30 days (5.0% vs.
.1%, p 0.06) and 1 year (7.8% vs. 3.9%, p 0.18).
dditionally, major bleeding events and vascular
omplications were significantly increased in the
AVI treatment group versus the medically treated
roup at 30 days and at 1 year.
tudy Comparisons
he observed 30-day mortality rate of 5.0% in the
AVI treatment arm is lower than previouslyeported studies, which range from 8.6% to 11.3%
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1335–8); in contrast, the 1-year mortality of 30.7% in TAVI
atients was higher than previously reported studies, rang-
ng from 22% to 26% (5–7). These discrepancies might be
ue to operator inexperience and/or earlier-generation valve
ystems as well as incomplete patient follow-up in previous
eports.
Aortic regurgitation is a common finding after TAVI and
s usually mild and paravalvular in nature (8,9). The 30-day
nd 1-year incidence of moderate or severe paravalvular
ortic regurgitation in the PARTNER trial was lower at
1.8% and 10.5%, respectively, in TAVI patients compared
ith 26% and 14% in other recently published studies (10).
uture Direction
he PARTNER trial investigated the efficacy and safety of
AVI in otherwise inoperable patients with severe symp-
omatic AS and further strengthened the momentum to-
ard TAVI in high-risk surgical patients. Continued ad-
ancements in delivery systems, valve durability, smaller
heath sizes, and operator experience will continue to make
AVI a viable option for patients with severe AS and
rohibitive surgical risk. A second randomized trial from the
ARTNER study (PARTNER II) investigating TAVI use
ith the new 18-F device in patients with high but not
rohibitive surgical risk is currently ongoing and offers to
hed light on TAVI use in surgical candidates. Further
valuation of transfemoral, transaxillary, and transapical
pproaches to TAVI in addition to newer devices, including
he Medtronic Core Valve system (Medtronic, Minneapo-
is, Minnesota), might broaden the suitability of TAVI for
wider range of patients.
The exclusion of patients with coronary stenoses requir-
ng revascularization, left ventricular ejection fraction
20%, and severe peripheral arterial disease limits the
sefulness of the results of the trial in everyday cardiology
ractice and necessitates further investigation. The current
hallenge, with the improving technical success of TAVI, is
nding the appropriate patient population for whom the
rocedure is best suited; this could be facilitated by the
evelopment of a “TAVI risk score” (11).
The threat of major stroke from embolic debris during
AVI remains a concerning dilemma. Although the overall
isk of permanent neurologic deficit is low, up to 72.7% of
atients had new clinically silent cerebral lesions detected by
agnetic resonance imaging in a small prospective study
12). Recent studies have evaluated the feasibility of embolic
rotection devices during TAVI (13), but their role remains
urrently undefined.
The regulatory pathway for approval in the U.S. of the
articular valve used in this trial is likely related to the
ncillary economic and quality-of-life analyses, the presen-
ation of the PARTNER cohort A (on high-risk though
perable patients who were randomized to TAVI vs. aorticalve surgery) in early 2011, and the interrelated device
volution to the 18-F system that is already used where this
alve has been approved for clinical use. Finally, the concept
f hospital operator team training in large scale is also
mportant. Furthermore, the futility question, the global
ealth system economic management issues, device evolu-
ion steps, further understanding and tackling TAVI com-
lications, and incorporation in the clinical practice in the
.S. are major challenges to be met. Evidently, many steps
oward making TAVI possible have been accomplished, but
ome more are still pending.
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